https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-17 / Eur. J. Immunol. 2015 Jun;45(6):1783-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-17 / Eur. J. Immunol. 2015 Jun;45(6):1783-932015-04-17 00:00:002019-02-15 08:45:04Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-16 / Tumour Biol. 2015 Sep;36(9):7121-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-16 / Tumour Biol. 2015 Sep;36(9):7121-312015-04-16 00:00:002019-02-15 09:22:44Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-14 / Chonnam Med J 2015 Apr;51(1):1-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-14 / Chonnam Med J 2015 Apr;51(1):1-72015-04-14 00:00:002019-02-15 08:51:23Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-12 / Cancer Immunol. Immunother. 2015 Jul;64(7):831-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-12 / Cancer Immunol. Immunother. 2015 Jul;64(7):831-422015-04-12 00:00:002019-02-15 08:45:10Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-09 / Cell 2015 Apr;161(2):205-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-09 / Cell 2015 Apr;161(2):205-142015-04-09 00:00:002019-02-15 08:35:55Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-07 / PLoS ONE 2015;10(4):e0120228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-07 / PLoS ONE 2015;10(4):e01202282015-04-07 00:00:002015-04-07 00:00:00High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-02 / Science 2015 May;348(6236):803-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-02 / Science 2015 May;348(6236):803-82015-04-02 00:00:002019-02-15 08:49:36Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-01 / Breast Care (Basel) 2015 Apr;10(2):109-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-01 / Breast Care (Basel) 2015 Apr;10(2):109-162015-04-01 00:00:002015-04-01 00:00:00Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-01 / Anticancer Res. 2015 Apr;35(4):2299-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-01 / Anticancer Res. 2015 Apr;35(4):2299-3032015-04-01 00:00:002015-04-01 00:00:00Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-27 / PLoS Pathog. 2015 Mar;11(3):e1004752
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-27 / PLoS Pathog. 2015 Mar;11(3):e10047522015-03-27 00:00:002019-02-15 08:48:01Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity
